FDA rejects ivonescimab lung cancer treatment
SMMT
Statements (4)
- Bearish
FDA did not approve Summit Therapeutics' China-developed lung cancer drug ivonescimab due to lack of statistically significant survival benefit.
- Bearish
FDA rejects ivonescimab treatment for lung cancer developed by Summit Therapeutics
- Bearish
FDA rejected ivonescimab, a lung cancer treatment from Summit Therapeutics and Akeso
- Neutral
FDA issued a Complete Response Letter regarding the BLA for ivonescimab in combination with platinum-containing chemotherapy for Summit Therapeutics